Overview

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

Status:
Completed
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
I-Mab Biopharma HongKong Limited